Exanthem disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

RASH MCID: EXN002 MIFTS: 57	Exanthem (RASH) malady Categories: Skin diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Exanthem

Aliases & Descriptions for Exanthem:

Name: Exanthem ¹² ¹⁴

Exanthema ¹² ⁴²

Rash ¹² ¹⁴

Rashes ⁴¹

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Symptoms and signs involving the skin and subcutaneous tissue

Rash and other nonspecific skin eruption

External Ids:

Disease Ontology ¹² DOID:0050486

ICD10 ³³ R21

ICD9CM ³⁵ 782.1

MeSH ⁴² D005076

NCIt ⁴⁷ C111884 C39594

SNOMED-CT ⁶⁴ 112625008 139684003 158230006 more

UMLS ⁶⁹ C0015230

Sources

Summaries for Exanthem

MedlinePlus : ⁴¹ a rash is an area of irritated or swollen skin. many rashes are itchy, red, painful, and irritated. some rashes can also lead to blisters or patches of raw skin. rashes are a symptom of many different medical problems. other causes include irritating substances and allergies. certain genes can make people more likely to get rashes. contact dermatitis is a common type of rash. it causes redness, itching, and sometimes small bumps. you get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. some rashes develop right away. others form over several days. although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. if it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to exanthema subitum and viral exanthem. An important gene associated with Exanthem is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Apraclonidine and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are Decreased viability and homeostasis/metabolism

Wikipedia : ⁷¹ An exanthem or exanthema (from Greek á¼Î¾Î¬Î½Î¸Î·Î¼Î± exÃ¡nthÄma, \"a breaking out\") is a widespread... more...

Sources

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem

Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)

id	Related Disease	Score	Top Affiliating Genes
1	exanthema subitum	12.2
2	viral exanthem	12.0
3	bacterial exanthem	11.8
4	hand, foot and mouth disease	11.2
5	contagious pustular dermatitis	10.8
6	hypersensitivity syndrome, carbamazepine-induced	10.8
7	alcoholic neuropathy	10.4	CD40LG CD79A
8	camptodactyly vertebral fusion	10.4	CD40LG CD79A
9	pineal region mature teratoma	10.3	EGFR ERBB2
10	egg allergy	10.3	CD40LG IL1RN NLRP3
11	dextrocardia	10.3	CD40LG CD79A IL1RN
12	spinal polio	10.3	CD40LG CD79A
13	megacolon	10.3	CD40LG CD79A PTS
14	rabies	10.3	CD40LG CD79A
15	cutaneous sclerosis	10.3	CRP IL1RN NLRP3
16	bile duct disease	10.3	EGFR HRAS KRAS
17	leiomyosarcoma	10.3	CD40LG CD79A CRP
18	unilateral retinoblastoma	10.3	CD40LG CD79A
19	precursor t-lymphoblastic lymphoma/leukemia	10.3	EGFR HRAS KRAS
20	malignant skin fibrous histiocytoma	10.3	HRAS KRAS
21	chronic mucocutaneous candidiasis	10.3	CD40LG CD79A CRP
22	kidney clear cell sarcoma	10.3	EGFR HRAS KRAS
23	ovarian serous cystadenocarcinoma	10.3	CD40LG CD79A CRP
24	mesangial proliferative glomerulonephritis	10.3	CD40LG CD79A
25	cyclotropia	10.3	CD40LG CD79A CRP
26	primary lacrimal atrophy	10.3	CD40LG CD79A TNFRSF1B
27	dermatomycosis	10.3	CD40LG CD79A CRP
28	colonic benign neoplasm	10.3	CD40LG CD79A MTOR
29	glycogen storage disease viii	10.3	CD40LG CD79A CRP
30	artery disease	10.3	CD40LG CD79A CRP
31	myxedema	10.3	EGFR HRAS KRAS
32	spastic entropion	10.3	CD40LG CD79A CRP
33	spastic diplegia infantile type	10.3	EGFR ERBB2 KRAS
34	hemangioma of orbit	10.3	CD40LG CD79A IL2
35	conjunctival vascular disease	10.3	CD40LG CD79A TNFRSF1B
36	delta chain disease	10.3	CD40LG CD79A
37	anomalous left coronary artery from the pulmonary artery	10.2	EGFR ERBB2 MTOR
38	arthus reaction	10.2	ERBB2 HRAS KRAS
39	st. louis encephalitis	10.2	CD40LG IL2 KRAS
40	brachial plexus neuropathy	10.2	EGFR HRAS KRAS
41	acinic cell breast carcinoma	10.2	CD40LG CD79A TNFRSF1B
42	central nervous system origin vertigo	10.2	CD40LG CD79A IL2
43	lymph node adenoid cystic carcinoma	10.2	CD40LG CD79A TNFRSF1B
44	choreatic disease	10.2	CD40LG CD79A TNFRSF1B
45	ovarian cystadenocarcinoma	10.2	EGFR ERBB2 VEGFA
46	vascular hemostatic disease	10.2	EGFR ERBB2 HRAS KRAS
47	trichostrongyloidiasis	10.2	CD40LG CD79A
48	wilkes stevenson syndrome	10.2	CRP IL2 NLRP3
49	anaerobic meningitis	10.2	CD79A EGFR VEGFA
50	endobronchial leiomyoma	10.2	CD40LG CRP IL1RN TNFRSF1B

Graphical network of the top 20 diseases related to Exanthem:

Sources

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

²⁶

id	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.66	HRAS MTOR KRAS EGFR
2	Decreased viability	GR00106-A-0	10.66	KRAS
3	Decreased viability	GR00221-A-1	10.66	MTOR KRAS PDGFRB EGFR KDR HRAS
4	Decreased viability	GR00221-A-2	10.66	KDR KRAS HRAS
5	Decreased viability	GR00221-A-3	10.66	KDR HRAS PDGFRB ERBB2
6	Decreased viability	GR00221-A-4	10.66	KDR MTOR PDGFRB EGFR ERBB2
7	Decreased viability	GR00301-A	10.66	KRAS
8	Decreased viability	GR00342-S-1	10.66	MTOR PDGFRB MAP2K7
9	Decreased viability	GR00342-S-2	10.66	MTOR
10	Decreased viability	GR00381-A-1	10.66	KRAS
11	Decreased cell migration	GR00055-A-1	9.8	EGFR HRAS KDR KRAS MTOR PDGFRB
12	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.73	EGFR ERBB2 HRAS MTOR PDGFRB VEGFA
13	Decreased viability with paclitaxel	GR00179-A-1	9.7	EGFR MTOR ERBB2
14	Decreased viability with paclitaxel	GR00179-A-2	9.7	MTOR
15	Decreased viability with paclitaxel	GR00179-A-3	9.7	EGFR MTOR
16	Increased cell migration	GR00055-A-3	9.02	EGFR HRAS KDR KRAS MTOR

MGI Mouse Phenotypes related to Exanthem:

⁴⁴ (show all 23)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.53	APOH CD4 CD40LG CD79A CRP EGFR
2	cellular	MP:0005384	10.47	CD4 CD40LG CD79A EGFR ERBB2 IL1RN
3	cardiovascular system	MP:0005385	10.45	CD40LG CRP EGFR ERBB2 HRAS IL1RN
4	mortality/aging	MP:0010768	10.42	APOH CD4 CD40LG EGFR ERBB2 HRAS
5	growth/size/body region	MP:0005378	10.41	KDR KRAS MTOR NLRP3 PDGFRB PTS
6	hematopoietic system	MP:0005397	10.4	CD4 CD40LG CD79A EGFR IL1RN IL2
7	endocrine/exocrine gland	MP:0005379	10.39	PDGFRB PTS TNFRSF1B VEGFA KRAS MAP2K7
8	immune system	MP:0005387	10.38	EGFR IL1RN IL2 KDR KRAS MTOR
9	integument	MP:0010771	10.37	KDR KRAS MAP2K7 NLRP3 PDGFRB PTS
10	behavior/neurological	MP:0005386	10.35	ERBB2 HRAS IL2 KDR KRAS MAP2K7
11	nervous system	MP:0003631	10.31	EGFR ERBB2 HRAS KDR KRAS MAP2K7
12	digestive/alimentary	MP:0005381	10.28	CD4 EGFR ERBB2 IL2 KRAS NLRP3
13	normal	MP:0002873	10.15	CD79A EGFR ERBB2 HRAS CD4 KDR
14	craniofacial	MP:0005382	10.14	HRAS KRAS PDGFRB TNFRSF1B VEGFA EGFR
15	muscle	MP:0005369	10.13	KDR KRAS MTOR PDGFRB PTS TNFRSF1B
16	liver/biliary system	MP:0005370	10.11	CD79A EGFR IL2 KDR KRAS NLRP3
17	neoplasm	MP:0002006	10.11	VEGFA CD79A EGFR ERBB2 HRAS IL2
18	no phenotypic analysis	MP:0003012	10.06	CD4 CD79A EGFR HRAS IL2 KDR
19	renal/urinary system	MP:0005367	10.02	CD40LG CD79A EGFR HRAS KRAS MTOR
20	reproductive system	MP:0005389	10	CD40LG EGFR ERBB2 IL1RN IL2 KRAS
21	respiratory system	MP:0005388	9.81	HRAS IL2 KDR KRAS MTOR TNFRSF1B
22	skeleton	MP:0005390	9.73	NLRP3 PDGFRB TNFRSF1B CD40LG EGFR ERBB2
23	vision/eye	MP:0005391	9.23	EGFR IL2 KDR KRAS MAP2K7 PDGFRB

Sources

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 919)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Apraclonidine

Approved

Phase 4,Phase 3

66711-21-5

2216

Gabapentin

Approved, Investigational

Phase 4,Phase 2

60142-96-3

3446

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Latanoprost

Approved, Investigational

Phase 4

130209-82-4

5282380 5311221

Benzoyl peroxide

Approved

Phase 4,Phase 3,Phase 1,Phase 2

94-36-0

7187

Clindamycin

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

18323-44-9

29029

Cetuximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1

205923-56-4

56842117 2333

Nevirapine

Approved

Phase 4,Phase 3,Phase 2

129618-40-2

4463

sodium fluoride

Approved

Phase 4,Phase 2

7681-49-4

Tacrolimus

Approved, Investigational

Phase 4,Phase 2,Phase 1

104987-11-3

445643 439492

Salicylic acid

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

69-72-7

338

Sorafenib

Approved, Investigational

Phase 4,Phase 2

284461-73-0

216239 406563

Triamcinolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2

124-94-7

31307

Rifampin

Approved

Phase 4,Phase 1,Phase 2

13292-46-1

5458213 5381226

Sunitinib

Approved, Investigational

Phase 4,Phase 1

341031-54-7, 557795-19-4

5329102

Efavirenz

Approved, Investigational

Phase 4,Phase 3,Phase 1

154598-52-4

64139

Epinephrine

Approved, Vet_approved

Phase 4,Phase 2,Phase 3

51-43-4

5816

Lidocaine

Approved, Vet_approved

Phase 4,Phase 3,Phase 1

137-58-6

3676

Petrolatum

Approved

Phase 4,Phase 3,Phase 1,Phase 2

8009-03-8

Doxycycline

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

564-25-0

54671203

Acetaminophen

Approved

Phase 4,Phase 3,Phase 1,Phase 2

103-90-2

1983

Aspirin

Approved, Vet_approved

Phase 4,Phase 2,Phase 1

50-78-2

2244

Azelaic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1

123-99-9

2266

Benzocaine

Approved

Phase 4,Phase 3,Phase 2,Early Phase 1

1994-09-7, 94-09-7

2337

Minocycline

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

10118-90-8

5281021

Betamethasone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2

378-44-9

9782

Pimecrolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2

137071-32-0

6447131 17753757

Ephedrine

Approved

Phase 4,Phase 2

299-42-3

9294

Pseudoephedrine

Approved

Phase 4,Phase 2

90-82-4

7028

Menthol

Approved

Phase 4,Phase 3

2216-51-5

16666

Vancomycin

Approved

Phase 4,Phase 3

1404-90-6

441141 14969

Azithromycin

Approved

Phase 4,Phase 3,Phase 2,Early Phase 1

83905-01-5

55185 53477736 447043

Apremilast

Approved, Investigational

Phase 4,Phase 3,Phase 2

608141-41-9

11561674

Peginterferon alfa-2a

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

198153-51-4

5360545

Ribavirin

Approved

Phase 4,Phase 3,Phase 1

36791-04-5

37542

Zinc

Approved

Phase 4,Phase 3,Phase 2,Phase 1

7440-66-6

32051 23994

Zinc oxide

Approved

Phase 4,Phase 3

1314-13-2

Prednisone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1

53-03-2

5865

Lamivudine

Approved, Investigational

Phase 4,Phase 2

134678-17-4

60825

Stavudine

Approved, Investigational

Phase 4

3056-17-5

18283

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

22916-47-8

4189

Everolimus

Approved

Phase 4,Phase 3,Phase 1,Phase 2

159351-69-6

6442177

Mycophenolate mofetil

Approved, Investigational

Phase 4,Phase 2

128794-94-5

5281078

Mycophenolic acid

Approved

Phase 4,Phase 2

24280-93-1

446541

Sirolimus

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

53123-88-9

5284616 6436030 46835353

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Amifostine

Approved, Investigational

Phase 4

20537-88-6

2141

Lamotrigine

Approved, Investigational

Phase 4,Phase 3,Phase 2

84057-84-1

3878

Morphine

Approved, Investigational

Phase 4,Phase 3

57-27-2

5288826

Primaquine

Approved

Phase 4

90-34-6

4908

Interventional clinical trials:

(show top 50) (show all 1717)

id	Name	Status	NCT ID	Phase
1	Elmex Gel Efficacy in Preventing White Spot Lesions	Unknown status	NCT00268138	Phase 4
2	Line Versus Spot Ablation in Persistent Atrial Fibrillation	Unknown status	NCT00196157	Phase 4
3	Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma	Unknown status	NCT01956942	Phase 4
4	A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder	Unknown status	NCT00837343	Phase 4
5	Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission	Unknown status	NCT01901666	Phase 4
6	Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome	Unknown status	NCT02424695	Phase 4
7	The Laser in Pseudoexfoliation (LIP) Study	Unknown status	NCT01704989	Phase 4
8	Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris	Unknown status	NCT01448733	Phase 4
9	A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne	Unknown status	NCT01422785	Phase 4
10	Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)	Unknown status	NCT01260571	Phase 4
11	Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)	Unknown status	NCT01553032	Phase 4
12	Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash	Completed	NCT00219466	Phase 4
13	Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT	Completed	NCT00647205	Phase 4
14	Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients	Completed	NCT01329731	Phase 4
15	Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients	Completed	NCT02184299	Phase 4
16	Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study	Completed	NCT00723515	Phase 4
17	MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study	Completed	NCT02424097	Phase 4
18	Genotype Based Personalized Prescription of Nevirapine	Completed	NCT00986063	Phase 4
19	Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients	Completed	NCT01768390	Phase 4
20	Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots	Completed	NCT01149876	Phase 4
21	Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants	Completed	NCT00702507	Phase 4
22	Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.	Completed	NCT01195194	Phase 4
23	Efficacy of Pentoxifylline on Chronic Kidney Disease	Completed	NCT00155246	Phase 4
24	Subcutaneous Amifostine Safety Study	Completed	NCT00158041	Phase 4
25	Comparison of the Effect of Fluoride Remineralizer Gel and Foam	Completed	NCT02490592	Phase 4
26	SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle	Completed	NCT01242852	Phase 4
27	A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster	Completed	NCT02152800	Phase 4
28	Bipolar Study in Adults at Least 18 Years of Age	Completed	NCT00067938	Phase 4
29	Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra	Completed	NCT01389557	Phase 4
30	A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nep	Completed	NCT00168857	Phase 4
31	FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra	Completed	NCT01656148	Phase 4
32	Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women	Completed	NCT00616239	Phase 4
33	Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients	Completed	NCT00882089	Phase 4
34	Oral Contraceptive Efficacy and Body Weight	Completed	NCT00662454	Phase 4
35	Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail	Completed	NCT02961998	Phase 4
36	Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)	Completed	NCT00928577	Phase 4
37	A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009)	Completed	NCT02143882	Phase 4
38	Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia	Completed	NCT00232232	Phase 4
39	Prednisolone Pharmacokinetics in Severe Asthma	Completed	NCT00662298	Phase 4
40	NOW Thai HAART Study	Completed	NCT00367731	Phase 4
41	Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails	Completed	NCT01703325	Phase 4
42	Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China	Completed	NCT02898922	Phase 4
43	Carotene and Retinol Efficacy Trial	Completed	NCT00712647	Phase 4
44	CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial	Completed	NCT00847912	Phase 4
45	Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis	Completed	NCT00617643	Phase 4
46	Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa	Completed	NCT01088516	Phase 4
47	Evaluation of an Herbal-Based De-Pigmenting System	Completed	NCT02138539	Phase 4
48	Treatment of Lower Extremity Spider Veins With Excel V	Completed	NCT01362192	Phase 4
49	Fractional CO2 Treatment of Acne Scars in Asians	Completed	NCT00748462	Phase 4
50	Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients	Completed	NCT01402089	Phase 4

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Sources

Genetic Tests for Exanthem

Sources

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

³⁹

Skin, T Cells, Testes, Neutrophil, Myeloid, Liver, Prostate

Sources

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 248)

id	Title	Authors	Year
1	Urticarial exanthem associated with Capnocytophaga canimorsus bacteremia after a dog bite. ( 27051842 )	Jordan C.S....Mengden S.J.	2016
2	Eruptive hypomelanosis in a child, a new viral exanthem. ( 26728822 )	Zawar V....Chuh A.	2016
3	Anogenital allergic contact dermatitis caused by methylchloroisothiazolinone, methylisothiazolinone and topical clotrimazole with subsequent generalized exanthem triggered by oral fluconazole. ( 27040872 )	Nasir S....Goldsmith P.	2016
4	Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies? ( 27103975 )	Chuh A....Lee A.	2016
5	Monitoring of human herpesviruses-6 and -7 DNA in saliva samples during the acute and convalescent phases of exanthem subitum. ( 27648817 )	Miyazaki Y....Yamada M.	2016
6	A mini-epidemic of eruptive hypomelanosis in three children of the same family; the first piece of epidemiological evidence for an infectious cause of a novel paraviral exanthem. ( 27038439 )	Chuh A....Bharatia P.	2016
7	"Tache noire": diagnostic clue in a febrile exanthem. ( 28038854 )	Velasco-Tamariz V....MaroA+as-JimAcnez L.	2016
8	Lateralized exanthem mimicking figurate inflammatory dermatosis of infancy after methimazole therapy. ( 27272160 )	Arrigo T....Altavilla D.	2016
9	Image Gallery: A case of unilateral laterothoracic exanthem. ( 27996140 )	Woo S.H....Park J.	2016
10	Stammbetontes Exanthem mit Allgemeinsymptomatik. ( 26972204 )	Delavari D....Hartmann M.	2016
11	Coxsackievirus A6 Polymorphic Exanthem in Israeli Children. ( 26463513 )	Renert-Yuval Y....Molho-Pessach V.	2016
12	Exanthem subitum (human herpesvirus-6 reactivation) after autologous stem cell transplantation. ( 26918962 )	Schlaweck S....Mayer K.	2016
13	Localized exanthem due to echovirus 9. ( 25919440 )	Drago F....Parodi A.	2015
14	Purpuric exanthem caused by Ross River virus infection. ( 25551310 )	Allanson B....Wood B.A.	2015
15	Unilateral Exanthem. ( 26120168 )	George A....Kanish B.	2015
16	Unilateral Laterothoracic Exanthem. ( 26187001 )	Leung A.K....Barankin B.	2015
17	Febrile Exanthem with Hyperferritinemia. ( 26705442 )	Caputo G.M....Ryan E.F.	2015
18	Superimposed lateralized exanthem of childhood: report of a case related to adenovirus infection. ( 24635078 )	Niedermeier A....Happle R.	2014
19	Vesiculobullous viral exanthem due to chikungunya in an infant. ( 25593800 )	Singh N....Dhodapkar R.	2014
20	Unilateral laterothoracic or asymmetric periflexural exanthem: is time to change the name of the disease? ( 25267301 )	Drago F....Rebora A.	2014
21	Eruptive hypomelanosis: a novel exanthem associated with viral symptoms in children. ( 25229328 )	Zawar V....Chuh A.	2014
22	Aminopenicillin-associated exanthem: lymphocyte transformation testing revisited. ( 25323308 )	Trautmann A....Kerstan A.	2014
23	Black heel (talon noir) associated with a viral exanthem. ( 24222298 )	Sardana K....Sagar V.	2013
24	Unilateral laterothoracic exanthem. ( 21989468 )	Gragasin F.S....Metelitsa A.I.	2012
25	Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. ( 22290027 )	Gavini A....Olszewski A.J.	2012
26	Acetaminophen-induced exanthem of the breasts. ( 22838093 )	Arora R....Maddox C.L.	2012
27	Febrile illness with papular and vesicular exanthem and ulceronecrotic plaques. ( 23106676 )	Castelo-Soccio L.A....Shah K.N.	2012
28	Histopathology of measles exanthem: a case with characteristic features and eosinophils. ( 22725635 )	Sheikine Y....Zimarowski M.J.	2012
29	Gianotti-Crosti syndrome, pityriasis rosea, asymmetrical periflexural exanthem, unilateral mediothoracic exanthem, eruptive pseudoangiomatosis, and papular-purpuric gloves and socks syndrome: a brief review and arguments for diagnostic criteria. ( 24470919 )	Chuh A....Sciallis G.	2012
30	A challenging case: Symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both? ( 22082466 )	Ozkaya E....Babuna G.	2011
31	Drug-induced exanthem following dabigatran. ( 21881034 )	Whitehead H....Hummel J.	2011
32	Asymmetrical periflexural exanthem of childhood with concurrence of molluscum contagiosum infection. ( 21457157 )	Baek Y.S....Son S.B.	2011
33	Papular exanthem discloses acute myeloid leukaemia: interphase fluorescence in situ hybridization revealed deletion of p53 and gain at 8q22/8q24/Tel8q without trisomy 8. ( 19438543 )	Kaune K.M....Emmert S.	2010
34	Transient linear eruption: asymmetric periflexural exanthem or blaschkitis. ( 20609153 )	Arun B....Salim A.	2010
35	Exanthem with cryopyrin associated periodic syndromes and consideration of IL-1 targeted therapy for neutrophilic predominant urticaria. ( 20657165 )	Wanderer A.A.	2010
36	Image in medicine. An exanthem with an annular pattern in a 2-year-old girl. Atypical viral exanthem with an annular pattern. ( 20838712 )	Rodgers C.J....Tey H.L.	2010
37	Infectious exanthem. ( 19375548 )	Patel N.N....Patel D.N.	2009
38	Unilateral laterothoracic exanthem and primary Epstein-Barr virus infection: case report. ( 19483526 )	Duarte A.F....Azevedo F.	2009
39	Symmetrical drug-related intertriginous and flexural exanthem due to oral risperidone. ( 19419476 )	Akay B.N....Sanli H.	2009
40	Morbilliform exanthem induced by imiquimod in a patient with drug-related immunosuppression. ( 19196306 )	Cavicchini S....Gianotti R.	2009
41	Asymmetrical periflexural exanthem exhibiting pseudoisomorphic KAPebner response in an adult. ( 19094120 )	Dar N.R....Raza N.	2009
42	Maculopapular exanthem from propolis: case report and review of systemic cutaneous and non-cutaneous reactions. ( 20059499 )	Komericki P....KrAonke B.	2009
43	An update on pityriasis rosea and other similar childhood exanthems. ( 19502983 )	Browning J.C.	2009
44	Exanthem subitum-associated encephalitis: nationwide survey in Japan. ( 19818937 )	Yoshikawa T....Asano Y.	2009
45	Varicella zoster virus associated acute aseptic meningitis without exanthem in an immunocompetent 14-year-old boy. ( 18316987 )	Leahy T.R....Butler K.M.	2008
46	African tick bite fever--papulovesicular exanthem with fever after staying in South Africa. ( 18021248 )	Schuster J....Hartmann K.	2008
47	Mercury pink exanthem after dental amalgam placement. ( 18269611 )	Pigatto P.D....Guzzi G.	2008
48	Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem. ( 18566552 )	Lam A....Klaustermeyer W.	2008
49	The exanthem of dengue fever: Clinical features of two US tourists traveling abroad. ( 17959270 )	Pincus L.B....Fox L.P.	2008
50	Unilateral laterothoracic exanthem with coincident evidence of Epstein-Barr virus reactivation: exploration of a possible link. ( 18319041 )	Zawar V....Chuh A.	2008

Sources

Genes for Exanthem

Genes related to Exanthem (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

id	Symbol	Description	Score	Implication
1	CD40LG	CD40 Ligand	26.68	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
2	EGFR	Epidermal Growth Factor Receptor	25.69	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
3	IL1RN	Interleukin 1 Receptor Antagonist	24.92	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
4	NLRP3	NLR Family Pyrin Domain Containing 3	24.85	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
5	PTS	6-Pyruvoyltetrahydropterin Synthase	24.75	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
6	CD79A	CD79a Molecule	24.59	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
7	KRAS	KRAS Proto-Oncogene, GTPase	24.56	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
8	HRAS	HRas Proto-Oncogene, GTPase	24.5	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
9	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	24.4	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
10	CRP	C-Reactive Protein	24.35	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
11	TNFRSF1B	TNF Receptor Superfamily Member 1B	24.11	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
12	MTOR	Mechanistic Target Of Rapamycin	23.89	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
13	MAP2K7	Mitogen-Activated Protein Kinase Kinase 7	23.73	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
14	IL2	Interleukin 2	23.72	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
15	KDR	Kinase Insert Domain Receptor	23.56	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
16	VEGFA	Vascular Endothelial Growth Factor A	23.4	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
17	PDGFRB	Platelet Derived Growth Factor Receptor Beta	23.13	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
18	APOH	Apolipoprotein H	22.11	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
19	CD4	CD4 Molecule	21.73	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
20	SENP8	SUMO/Sentrin Peptidase Family Member, NEDD8 Specific	14.55	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)

Sources

Variations for Exanthem

Sources

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Sources

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 86)

id	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶² Show member pathways Immune System ⁶² Neutrophil degranulation ⁶²	13.98	CD4 CD40LG CD79A CRP EGFR ERBB2
2	ERK Signaling ⁶⁰ Show member pathways ILK Signaling ⁶⁰ MAPK Signaling ⁶⁰ Molecular Mechanisms of Cancer ⁶⁰ Rho Family GTPases ⁶⁰	13.93	CD4 CD40LG EGFR ERBB2 HRAS IL2
3	GPCR Pathway ⁶⁰ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁰ Estrogen Pathway ⁶⁰ NFAT in Immune Response ⁶⁰ P2Y Receptor Signaling ⁶⁰ Pancreatic Adenocarcinoma ⁶⁰ Paxillin Interactions ⁶⁰ Ras Pathway ⁶⁰	13.81	CD4 CD79A EGFR ERBB2 HRAS IL2
4	Activation of cAMP-Dependent PKA ⁶⁰ Show member pathways Activation of PKA through GPCR ⁶⁰ cAMP Pathway ⁶⁰ PKA Signaling ⁶⁰	13.65	CRP EGFR ERBB2 HRAS IL2 KDR
5	PEDF Induced Signaling ⁶⁰ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁰ Cytokine-cytokine receptor interaction ³⁷ Endothelin-1 Signaling Pathway ⁶⁰ Glucocorticoid Receptor Signaling ⁶⁰ IL-6 Pathway ⁶⁰ MIF Mediated Glucocorticoid Regulation ⁶⁰ MIF Regulation of Innate Immune Cells ⁶⁰ NFAT Signaling and Lymphocyte Interactions ⁶⁰ PGC1Alpha Pathway ⁶⁰ RAR-Gamma-RXR-Alpha Degradation ⁶⁰ STAT3 Pathway ⁶⁰	13.61	CD4 CD40LG EGFR ERBB2 HRAS IL2
6	Developmental Biology ⁶² Show member pathways Axon guidance ⁶²	13.58	EGFR ERBB2 HRAS IL2 KDR KRAS
7	Class I MHC mediated antigen processing and presentation ⁶² Show member pathways Adaptive Immune System ⁶² Antigen processing- Ubiquitination and Proteasome degradation ⁶²	13.55	CD4 CD40LG CD79A EGFR ERBB2 HRAS
8	TGF-Beta Pathway ⁶⁰ Show member pathways JAK-STAT Pathway ⁶⁰ JNK Pathway ⁶⁰ MAPK Family Pathway ⁶⁰ Regulation of eIF4 and p70S6K ⁶⁰ SOCS Pathway ⁶⁰	13.54	CD4 EGFR ERBB2 HRAS IL2 KDR
9	Akt Signaling ⁶⁰ Show member pathways p38 Signaling ⁶⁰ Tec Kinases Signaling ⁶⁰	13.43	CD4 CD40LG EGFR ERBB2 HRAS IL2
10	CREB Pathway ⁶⁰ Show member pathways Activation of PKC through GPCR ⁶⁰ Intracellular Calcium Signaling ⁶⁰ IP3 Pathway ⁶⁰	13.42	CD79A EGFR ERBB2 HRAS IL2 KDR
11	Nanog in Mammalian ESC Pluripotency ⁶⁰ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁰ eNOS Signaling ⁶⁰ GSK3 Signaling ⁶⁰	13.37	EGFR ERBB2 HRAS IL2 KDR KRAS
12	Cytokine Signaling in Immune system ⁶² Show member pathways Signaling by Interleukins ⁶²	13.35	CD4 CD40LG EGFR ERBB2 HRAS IL1RN
13	IL-2 Pathway ⁶⁰ Show member pathways ErbB Family Pathway ⁶⁰ ErbB2-ErbB3 Heterodimers ⁶⁰ ErbB4 Pathway ⁶⁰ Growth Hormone Signaling ⁶⁰ HMGB1 Pathway ⁶⁰ IL-4 Pathway ⁶⁰ LPS Stimulated MAPK Signaling ⁶⁰ PACAP Signaling ⁶⁰ PI3K Signaling in B-Lymphocyte ⁶⁰ Prolactin Signaling ⁶⁰ Thrombopoietin Pathway ⁶⁰ TREM1 Pathway ⁶⁰ UVC-Induced MAPK Signaling ⁶⁰	13.28	CD79A EGFR ERBB2 HRAS IL2 KRAS
14	PAK Pathway ⁶⁰ Show member pathways Antioxidant Action of Vitamin-C ⁶⁰ Epithelial Adherens Junctions ⁶⁰	13.24	CD4 CD40LG EGFR ERBB2 HRAS IL2
15	Phospholipase-C Pathway ⁶⁰ Show member pathways PTEN Pathway ⁶⁰	13.15	CD79A EGFR HRAS IL2 KDR KRAS
16	p70S6K Signaling ⁶⁰ Show member pathways mTOR Pathway ⁶⁰ Renin-Angiotensin Pathway ⁶⁰	13.14	EGFR HRAS IL2 KDR KRAS MTOR
17	Toll-Like receptor Signaling Pathways ⁶¹ Show member pathways IL-1 Family Signaling Pathways ⁶¹ Immune response IL-1 signaling pathway ²¹ Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²¹ Inflammasome Activation Pathways ⁶¹ Mucin expression in CF via TLRs, EGFR signaling pathways ²¹ NOD-like receptor signaling pathway ³⁷ NOD-like Receptor Signaling Pathways ⁶¹ Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶¹	13.07	EGFR HRAS IL1RN KRAS MAP2K7 NLRP3
18	Glioma ³⁷ Show member pathways Breast cancer ³⁷ EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Prostate cancer ³⁷ Signaling Pathways in Glioblastoma ¹ Vemurafenib Pathway, Pharmacodynamics ⁵⁸	13.05	EGFR ERBB2 HRAS KDR KRAS MAP2K7
19	Development Angiotensin activation of ERK ²¹ Show member pathways Cell adhesion Integrin inside-out signaling ²¹ Development ACM2 and ACM4 activation of ERK ²¹ Development Angiotensin signaling via PYK2 ²¹ Development EDNRB signaling ²¹ Development EPO-induced MAPK pathway ²¹ Development G-Proteins mediated regulation MARK-ERK signaling ²¹ Signal transduction IP3 signaling ²¹	12.99	CD79A EGFR HRAS KRAS PDGFRB TNFRSF1B
20	Regulation of lipid metabolism Insulin signaling-generic cascades ²¹ Show member pathways acetyl-CoA biosynthesis from citrate ¹ Butyrate-induced histone acetylation ¹ Cell adhesion PLAU signaling ²¹ Class IB PI3K non-lipid kinase events ¹ Development CNTF receptor signaling ²¹ Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²¹ ErbB2/ErbB3 signaling events ¹ Glucose Homeostasis ¹ Insulin signaling pathway ³⁷ IRS activation ⁶² Signal attenuation ⁶² Transcription Receptor-mediated HIF regulation ²¹ Translation Regulation of EIF2 activity ²¹ Translation Regulation of EIF4F activity ²¹ Translation Insulin regulation of translation ²¹	12.99	EGFR ERBB2 HRAS KRAS MTOR VEGFA
21	NFAT and Cardiac Hypertrophy ⁶⁰ Show member pathways IGF1R Signaling ⁶⁰ Signaling Involved in Cardiac Hypertrophy ⁶⁰	12.97	EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
22	Focal Adhesion ³⁷ ¹ Show member pathways HGF Pathway ⁶⁰ Integrin-mediated Cell Adhesion ¹	12.97	EGFR ERBB2 HRAS KDR KRAS MAP2K7
23	TNFR1 Pathway ⁶⁰ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²¹ Apoptosis through Death Receptors ⁶⁰ Apoptotic Pathways Triggered By HIV1 ⁶⁰ DR3 Signaling ⁶⁰ Fas Signaling ⁶⁰ GITR Pathway ⁶⁰ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶² TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁰ TRAIL Pathway ⁶⁰ TWEAK Pathway ⁶⁰	12.94	CD4 HRAS KRAS MAP2K7 TNFRSF1B
24	Development HGF signaling pathway ²¹ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²¹ Apoptosis and survival NGF signaling pathway ²¹ Apoptosis and survival Role of CDK5 in neuronal death and survival ²¹ Development Neurotrophin family signaling ²¹ MET activates PTPN11 ⁶² MET activates STAT3 ⁶² Neurotrophin signaling pathway ³⁷ Renal cell carcinoma ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.9	ERBB2 HRAS KRAS MAP2K7 MTOR VEGFA
25	Development Endothelin-1/EDNRA signaling ²¹ Show member pathways Cytoskeleton remodeling FAK signaling ²¹ Development Endothelin-1/EDNRA transactivation of EGFR ²¹ Estrogen signaling pathway ³⁷ GnRH signaling pathway ³⁷ Inflammatory mediator regulation of TRP channels ³⁷	12.89	EGFR HRAS KDR KRAS MAP2K7 MTOR
26	Ras signaling pathway ³⁷ Show member pathways Rap1 signaling pathway ³⁷	12.82	EGFR HRAS KDR KRAS PDGFRB VEGFA
27	Downstream signaling events of B Cell Receptor (BCR) ⁶² Show member pathways Activation of RAS in B cells ⁶² Signaling by the B Cell Receptor (BCR) ⁶²	12.82	CD79A EGFR ERBB2 HRAS KRAS MTOR
28	MAPK signaling pathway ³⁷ ¹	12.78	EGFR HRAS KRAS MAP2K7 PDGFRB
29	NF-KappaB Family Pathway ⁶⁰ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁰	12.77	CD40LG EGFR IL2 KDR TNFRSF1B
30	Pathways in cancer ³⁷	12.76	EGFR ERBB2 HRAS KRAS MTOR PDGFRB
31	TRAF Pathway ⁶⁰ Show member pathways 14-3-3 Induced Apoptosis ⁶⁰ TNF Superfamily Pathway ⁶⁰ Toll-Like Receptors Pathway ⁶⁰	12.72	CD40LG HRAS KDR MAP2K7 TNFRSF1B VEGFA
32	Immune response NFAT in immune response ²¹ Show member pathways Immune response CD28 signaling ²¹ Immune response ICOS pathway in T-helper cell ²¹ Immune response T cell receptor signaling pathway ²¹	12.72	CD4 CD40LG CD79A HRAS IL2 MAP2K7
33	Immune response Fc epsilon RI pathway ²¹ Show member pathways Fc epsilon RI signaling pathway ³⁷ Fc-epsilon receptor I signaling in mast cells ¹ Immune response BCR pathway ²¹ VEGF signaling pathway ³⁷	12.69	CD79A HRAS KDR KRAS MAP2K7 VEGFA
34	Immune response IL-23 signaling pathway ²¹ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁰ Development Angiopoietin - Tie2 signaling ²¹ Development PDGF signaling via STATs and NF-kB ²¹ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²¹ Rac1/Pak1/p38/MMP-2 pathway ¹	12.68	CD4 EGFR ERBB2 HRAS IL2 KRAS
35	Development ERBB-family signaling ²¹ Show member pathways Development EGFR signaling pathway ²¹ EGF Pathway ⁶⁰ EGFR Signaling Pathway ⁶³ ErbB receptor signaling network ¹ GRB7 events in ERBB2 signaling ⁶² PLCG1 events in ERBB2 signaling ⁶²	12.65	EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
36	NF-kappaB Signaling ⁴	12.63	CD40LG CD79A IL1RN IL2 TNFRSF1B
37	4-1BB Pathway ⁶⁰ Show member pathways CD27 Pathway ⁶⁰ CD40 Signaling ⁶⁰ CMV and MAPK Pathways ⁶⁰ NF-KappaB Activation by EBV ⁶⁰ NF-kappaB Activation by Viruses ⁶⁰ PKR Pathway ⁶⁰ SUMO Pathway ⁶⁰ TNFR2 Pathway ⁶⁰	12.6	CD4 CD40LG EGFR HRAS KRAS MAP2K7
38	Prolactin Signaling Pathway ¹ ³⁷ Show member pathways Development Prolactin receptor signaling ²¹ Leptin signaling pathway ¹	12.58	ERBB2 HRAS IL1RN KRAS MTOR
39	MicroRNAs in cancer ³⁷	12.58	EGFR ERBB2 HRAS KRAS MTOR PDGFRB
40	T cell receptor signaling pathway ³⁷ Show member pathways T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.53	CD4 CD40LG HRAS IL2 KRAS MAP2K7
41	Phospholipase D signaling pathway ³⁷ Show member pathways Choline metabolism in cancer ³⁷	12.5	EGFR HRAS KRAS MTOR PDGFRB
42	VEGF Pathway (Qiagen) ⁶⁰ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁰ Development VEGF-family signaling ²¹ Neurophilin interactions with VEGF and VEGFR ⁶² VEGF Family Ligands and Receptor Interactions ⁶⁰	12.46	EGFR HRAS KDR KRAS

Exanthem (RASH) malady

Aliases & Classifications for Exanthem

Aliases & Descriptions for Exanthem:

Classifications:

External Ids:

Summaries for Exanthem

Related Diseases for Exanthem

Diseases in the Exanthem family:

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Exanthem:

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Exanthem:

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Cochrane evidence based reviews: exanthema

Genetic Tests for Exanthem

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

Publications for Exanthem

Articles related to Exanthem:

Genes for Exanthem

Genes related to Exanthem (0 elite genes):

Variations for Exanthem

Expression for Exanthem

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing: